Skip to main content
. 2023 Feb 23;14:1025. doi: 10.1038/s41467-023-36541-w

Fig. 5. The 11β-hydroxysteroid dehydrogenase type 1 inhibitor, AZD4017, prevents the decrease in serum osteocalcin (A and B) and P1NP (C and D) and increase in CTX (E and F) levels associated with 7 days of prednisolone+placebo treatment.

Fig. 5

A Serum osteocalcin levels pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. B Change in serum osteocalcin levels in AZD4017+prednisolone and placebo+prednisolone groups. C Serum P1NP levels pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. D Change in serum P1NP levels in AZD4017+prednisolone and placebo+prednisolone groups. E Serum CTX levels pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. F Change in serum CTX levels in AZD4017+prednisolone and placebo+prednisolone groups. Data are medians and error bars are IQR. Data points represent individual patients. AZD4017 + prednisolone; n = 15, placebo+prednisolone n = 15. (Light blue circles = pre-treatment AZD4017 + prednisolone, blue squares = post-treatment AZD4017 + prednisolone, pink circles = pre-treatment placebo+prednisolone, red squares = post-treatment placebo+prednisolone). Statistical tests: Wilcoxon signed-rank test; Fig. 5A, paired two-tailed t-test; Fig. 5C and E and generalised linear models adjusting for baseline variability in each specified outcome; Fig. 5B, D and F.